Founder & CEO
Caroline Jansen is the founder & CEO of Oblita Therapeutics and takes up the responsibility for overall business management. She has a background of 15 years in public affairs (local authorities, federal/Belgian government and European parliament) and obtained a MA in Political Science at the Catholic University of Leuven. She then specialized in International Diplomacy and Management at Stellenbosch University (South-Africa) and obtained several management certificates afterwards (as well in private sector as public sector management). She used to work for different parliaments (Belgian and European) as well as a cabinet advisor for the Prime Minister of Belgium and for the Belgian Minister of Economics, Foreign Trade, Energy and Science Policy. She continued her career in advising on public affairs within pharmaceutical industry. Her background also includes working in the Lobby industry (the largest employer’s / entrepreneur’s organization in Belgium) as a Director of Services for Companies and as a Director Lobby & Public Affairs.

Head of Drug Development and Clinical Supplies

Sam Corveleyn is a seasoned Senior Chemistry, Manufacturing, and Controls (CMC) Consultant, Managing Director of SACOPHAR BV, with over 25 years of experience in the biopharmaceutical industry. Holding a PhD in Pharmaceutical Technology from the University of Ghent and certification as an EU Qualified Person, he has a proven track record of advancing assets through various CMC stages. He has expertise in successfully leading small molecules, live biotherapeutics, and biologics, from preclinical development to Phase 3 clinical trials. His leadership in biopharmaceutical process and formulation development supported preclinical and clinical studies, securing regulatory approvals in both the U.S. (FDA IND) and Europe (CTA filings). Sam is also a guest lecturer at Ghent University, presenting case studies to students in the Master’s program in Pharmaceutical Sciences. Additionally, he serves as an independent external expert for the Research Foundation Flanders (FWO), advising on the assessment and evaluation of research funding proposals. He is also recognized as an inventor on several patent applications, further demonstrating their influence and expertise in the biopharmaceutical field.

Cinical Head of Animal Health

Dr Lima is a post-doc research fellow at Fiocruz, Bahia, Brazil. She was the principal investigator for an efficacy study of D121 for the treatment of canine visceral leishmaniasis. Dr Lima graduated as a veterinary surgeon in 2011, from Universidade Federal da Bahia, Brazil, with a MSc in pathology obtained from FIOCRUZ in 2013, and a PhD obtained from FIOCRUZ in 2017, with a sandwich PhD at University of Surrey (UK). For the last decade she has specialized in veterinary pathology and visceral leishmaniasis. Dr Lima worked with splenic white pulp disruption and its effects on the severity of visceral leishmaniasis during her MSc in pathology. As a doctoral researcher, she studied the histological changes observed in the liver of dogs with visceral leishmaniasis and the clinical correlations of these changes. She also focused on the granulomatous response in the liver, and its role in parasite control and clinical status to provide background information increasing understanding of the human disease. Dr Lima is also a lecturer at a private university in Brazil, where she teaches general pathology to medical school students.

Head of Business Strategy

Alain De Keyser is a seasoned start-up and scale-up mentor with over 25 years of board-level experience in technology companies. He has successfully facilitated over 30 technology transfers in deep tech and renewable energy sectors, contributing to the commercialization of innovative technologies. Alain De Keyser has incubated and mentored numerous start-ups, achieving a success rate exceeding 90%. Alain’s focus lies in strategic positioning, venture development coaching, and new business creation in knowledge-driven domains such as deep tech, e-health and medtech, sustainable energy, materials, circularity, and digital transformation. As a managing partner in ProductArchitects, Alain helps companies transform concepts into products, services, strategies, or ventures efficiently and effectively by leveraging design sprint methodologies rooted in design thinking, systems thinking and behavioral design.

Head of Medical Affairs & Pharmacovigilance

Ludo Haazen obtained his medical degree from the Catholic University of Leuven in Belgium in 1985. He then led several clinical development projects for pharmaceutical companies including Roche SA, Janssen Research Foundation (JNJ), Orthovita INc, TiGenix nv, and others, and this in numerous therapeutic areas. Ludo Haazen has cumulated over 30 years of experience in clinical development and medical affairs, from first-in-man to post marketing studies. He has a deep understanding of the drug development business and was involved in two biotech start-up companies. Ludo also teaches in pharmaceutical medicine at the Free University of Brussels.